{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-26-000082","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2026-08-05T20:03:09+00:00","discovered_at":"2026-08-05T20:04:00.219130+00:00","generated_at":"2026-08-05T20:04:34.859747+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Editas Medicine Q2 net loss narrows to $18.2M; EDIT-401 on track for CTN submission","bullets":["Net loss $18.2M ($0.15/sh) vs $53.2M ($0.63/sh) in Q2 2025; collaboration revenue up to $11.9M.","Cash $211.6M as of June 30, 2026, up from $146.6M; cash runway into H2 2028.","EDIT-401 preclinical data shows ~90% mean reduction in LDL-C, Lp(a), ApoB in NHPs; CTN submission planned this month.","Phase 1/2 trial for HeFH to start; data update expected Q1 2027.","Board: Elliott Levy resigned; Patrick Ellinor appointed as independent director."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-26-000082","json":"https://secwatch.observer/filing/0001650664-26-000082.json","markdown":"https://secwatch.observer/filing/0001650664-26-000082.md","text":"https://secwatch.observer/filing/0001650664-26-000082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000082/0001650664-26-000082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000082/edit-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:04:34.859747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}